[go: up one dir, main page]

WO2006066599A3 - Mas related g protein coupled receptors as drug targets - Google Patents

Mas related g protein coupled receptors as drug targets Download PDF

Info

Publication number
WO2006066599A3
WO2006066599A3 PCT/DK2005/050011 DK2005050011W WO2006066599A3 WO 2006066599 A3 WO2006066599 A3 WO 2006066599A3 DK 2005050011 W DK2005050011 W DK 2005050011W WO 2006066599 A3 WO2006066599 A3 WO 2006066599A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein coupled
coupled receptors
drug targets
mas related
mas
Prior art date
Application number
PCT/DK2005/050011
Other languages
French (fr)
Other versions
WO2006066599A2 (en
Inventor
Leif Kongskov Larsen
Original Assignee
Rheoscience As
Leif Kongskov Larsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rheoscience As, Leif Kongskov Larsen filed Critical Rheoscience As
Priority to EP05821505A priority Critical patent/EP1835928A2/en
Publication of WO2006066599A2 publication Critical patent/WO2006066599A2/en
Publication of WO2006066599A3 publication Critical patent/WO2006066599A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Summary The present invention relates to G protein coupled receptors of the MAS related G protein coupled receptor family. The present invention furthermore relates to modulation of the activity of these receptors as a tool in treating 5 disorders such as obesity, and/or diabetes, and/or cardiovascular diseases.
PCT/DK2005/050011 2004-12-22 2005-12-21 Mas related g protein coupled receptors as drug targets WO2006066599A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05821505A EP1835928A2 (en) 2004-12-22 2005-12-21 Mas related g protein coupled receptors as drug targets

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63844504P 2004-12-22 2004-12-22
US60/638,445 2004-12-22
DKPA200401980 2004-12-22
DKPA200401980 2004-12-22

Publications (2)

Publication Number Publication Date
WO2006066599A2 WO2006066599A2 (en) 2006-06-29
WO2006066599A3 true WO2006066599A3 (en) 2006-08-17

Family

ID=35841850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/050011 WO2006066599A2 (en) 2004-12-22 2005-12-21 Mas related g protein coupled receptors as drug targets

Country Status (2)

Country Link
EP (1) EP1835928A2 (en)
WO (1) WO2006066599A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515858A (en) 2023-08-18 2025-04-16 美商英塞特公司 Bicyclic heterocycles as mrgprx2 antagonists
US20250243208A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025191018A1 (en) * 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Mrgpre binding agent for use in the treatment of inflammatory and pain disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064458A1 (en) * 1998-06-08 1999-12-16 Trustees Of Boston University Novel methods for identifying modulators of mitochondrial anion carrier activity
WO2001020327A1 (en) * 1999-09-15 2001-03-22 Astrazeneca Ab Spa in a screening method for modulators of glucokinase
WO2001062797A2 (en) * 2000-02-23 2001-08-30 Pharmacia & Upjohn Company G protein-coupled receptors
WO2001072840A2 (en) * 2000-03-27 2001-10-04 Pe Corporation (Ny) Isolated human g-protein coupled receptors of the mas proto-oncogene subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof
WO2001083555A2 (en) * 2000-05-04 2001-11-08 California Institute Of Technology Pain signaling molecules
WO2001094951A2 (en) * 2000-06-08 2001-12-13 Board Of Regents, The University Of Texas System Inhibitors of c-reactive protein induced inflammation
US20030162252A1 (en) * 2000-06-30 2003-08-28 Masanori Miwa Novel g protein-coupled receptor protein and dna thereof
WO2004040000A2 (en) * 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
WO2004042402A2 (en) * 2002-11-04 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064458A1 (en) * 1998-06-08 1999-12-16 Trustees Of Boston University Novel methods for identifying modulators of mitochondrial anion carrier activity
WO2001020327A1 (en) * 1999-09-15 2001-03-22 Astrazeneca Ab Spa in a screening method for modulators of glucokinase
WO2001062797A2 (en) * 2000-02-23 2001-08-30 Pharmacia & Upjohn Company G protein-coupled receptors
WO2001072840A2 (en) * 2000-03-27 2001-10-04 Pe Corporation (Ny) Isolated human g-protein coupled receptors of the mas proto-oncogene subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof
WO2001083555A2 (en) * 2000-05-04 2001-11-08 California Institute Of Technology Pain signaling molecules
WO2001094951A2 (en) * 2000-06-08 2001-12-13 Board Of Regents, The University Of Texas System Inhibitors of c-reactive protein induced inflammation
US20030162252A1 (en) * 2000-06-30 2003-08-28 Masanori Miwa Novel g protein-coupled receptor protein and dna thereof
WO2004040000A2 (en) * 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
WO2004042402A2 (en) * 2002-11-04 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BUIST A ET AL: "Identification of a novel peptide ligand family for MrgX1 and MrgX2 using reverse pharmacology.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, pages Abstract No. 480.10 URL - http://sf, XP009063135 *
COLLINS C A ET AL: "PROSPECTS FOR OBESITY TREATMENT: MCH RECEPTOR ANTAGONISTS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 4, no. 4, 1 April 2003 (2003-04-01), pages 386 - 394, XP009060720, ISSN: 1472-4472 *
MONNOT C ET AL: "CLONING AND FUNCTIONAL CHARACTERIZATION OF A NOVEL MAS-RELATED GENE MODULATING INTRACELLULAR ANGIOTENSIN II ACTIONS", MOLECULAR ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 5, no. 10, October 1991 (1991-10-01), pages 1477 - 1487, XP002927594, ISSN: 0888-8809 *
ZHANG L ET AL: "Cloning and expression of MRG receptors in macaque, mouse, and human", MOLECULAR BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 133, no. 2, 18 February 2005 (2005-02-18), pages 187 - 197, XP004750318, ISSN: 0169-328X *
ZYLKA M J ET AL: "Atypical expansion in mice of the sensory neuron-specific Mrg G protein-coupled receptor family", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 100, no. 17, 19 August 2003 (2003-08-19), pages 10043 - 10048, XP002287772, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2006066599A2 (en) 2006-06-29
EP1835928A2 (en) 2007-09-26

Similar Documents

Publication Publication Date Title
WO2007109354A3 (en) Peptide-peptidase inhibitor conjugates and methods of using same
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008074329A3 (en) Modulation of activity of proneurotrophins
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2006012577A3 (en) Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
WO2006129178A8 (en) Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2006108965A3 (en) Npy antagonists, preparation and use
WO2007022257A3 (en) Monocyclic and bicyclic compounds and methods of use
WO2003066604A3 (en) Novel aryl- and heteroarylpiperazines
WO2007009894A3 (en) Peptides for use in the treatment of obesity
WO2007120655A3 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
EP1771188A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY, INSULIN-ASSOCIATED DISEASES, AND HYPERCHOLESTEROLEMIA
WO2007120718A3 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2007120688A3 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2004005262A8 (en) New neuropeptide y y5 receptor antagonists
WO2006002387A3 (en) Gdf3 propeptides and related methods
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2006078853A3 (en) Thioredoxin interacting protein (txnip) as regulator of vascular function
WO2007022305A3 (en) 2-aminoimidazopyridines for treating neurodegenerative diseases
WO2002062780A3 (en) Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
WO2007133983A3 (en) 2-aminobenzimidazoles for treating neurodegenerative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005821505

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005821505

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005821505

Country of ref document: EP